Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
30.12 USD | +13.62% | +11.24% | -11.14% |
05:09pm | Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating | MT |
05-07 | Transcript : Pacira BioSciences, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.14% | 1.23B | |
+33.02% | 700B | |
-4.82% | 358B | |
+19.01% | 330B | |
+3.47% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+5.22% | 161B | |
-2.14% | 157B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- Pacira BioSciences Says Preliminary Data Show 2023 Sales Rose 1.2% From Year Earlier, Topping Consensus